(3) Tumor Plasticity: Preclinical models overrepresented ASCL1-driven SCLC subtypes with stable DLL3 expression, whereas NEUROD1-dominant subtypes show epigenetic DLL3 suppression under therapeutic pressure (26). This evidence concerns the gene DLL3 and small cell lung carcinoma.